These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1132 related items for PubMed ID: 10994545

  • 1. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U, Harms DO, Schlüter S, Jorch N, Spaar HJ, Nürnberger W, Völpel S, Gutjahr P, Schrappe M, Janka G, Kabisch H.
    Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
    [Abstract] [Full Text] [Related]

  • 2. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
    Basso G, Veltroni M, Valsecchi MG, Dworzak MN, Ratei R, Silvestri D, Benetello A, Buldini B, Maglia O, Masera G, Conter V, Arico M, Biondi A, Gaipa G.
    J Clin Oncol; 2009 Nov 01; 27(31):5168-74. PubMed ID: 19805690
    [Abstract] [Full Text] [Related]

  • 3. [In vitro drug resistance as independent prognostic factor in the study COALL-O5-92 Treatment of childhood acute lymphoblastic leukemia; two-tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study COALL-06-97].
    Janka-Schaub GE, Harms DO, den Boer ML, Veerman AJ, Pieters R.
    Klin Padiatr; 1999 Nov 01; 211(4):233-8. PubMed ID: 10472556
    [Abstract] [Full Text] [Related]

  • 4. [Prognostic value of both detection of lymphoblasts in the period of early treatment and minimal residual disease in childhood acute lymphoblastic leukemia].
    Tie LJ, Gu LJ, Song DL, Jiang LM, Xue HL, Tang JY, Dong L, Pan C, Chen J, Ye H, Wang YP, Chen J.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan 01; 26(1):6-9. PubMed ID: 15946500
    [Abstract] [Full Text] [Related]

  • 5. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
    Raciborska A, Wypych A, Rokicka-Milewska R, Siedlecki JA, Kulik J.
    Przegl Lek; 2004 Jan 01; 61 Suppl 2():62-6. PubMed ID: 15686049
    [Abstract] [Full Text] [Related]

  • 6. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
    Attarbaschi A, Mann G, Panzer-Grümayer R, Röttgers S, Steiner M, König M, Csinady E, Dworzak MN, Seidel M, Janousek D, Möricke A, Reichelt C, Harbott J, Schrappe M, Gadner H, Haas OA.
    J Clin Oncol; 2008 Jun 20; 26(18):3046-50. PubMed ID: 18565891
    [Abstract] [Full Text] [Related]

  • 7. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
    Kwok CS, Kham SK, Ariffin H, Lin HP, Quah TC, Yeoh AE.
    Pediatr Blood Cancer; 2006 Sep 20; 47(3):299-304. PubMed ID: 16302217
    [Abstract] [Full Text] [Related]

  • 8. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.
    Cavé H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, Bakkus M, Thielemans K, Grandchamp B, Vilmer E.
    N Engl J Med; 1998 Aug 27; 339(9):591-8. PubMed ID: 9718378
    [Abstract] [Full Text] [Related]

  • 9. Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements.
    Gameiro P, Mortuza FY, Hoffbrand AV, Foroni L.
    Haematologica; 2002 Nov 27; 87(11):1126-34. PubMed ID: 12414341
    [Abstract] [Full Text] [Related]

  • 10. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.
    Sutton R, Venn NC, Tolisano J, Bahar AY, Giles JE, Ashton LJ, Teague L, Rigutto G, Waters K, Marshall GM, Haber M, Norris MD, Australian and New Zealand Children's Oncology Group.
    Br J Haematol; 2009 Aug 27; 146(3):292-9. PubMed ID: 19500099
    [Abstract] [Full Text] [Related]

  • 11. Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study.
    Madzo J, Zuna J, Muzíková K, Kalinová M, Krejcí O, Hrusák O, Otová B, Starý J, Trka J.
    Cancer; 2003 Jan 01; 97(1):105-13. PubMed ID: 12491511
    [Abstract] [Full Text] [Related]

  • 12. PCR detection of clonal IgH and TCR gene rearrangements at the end of induction as a non-remission criterion in children with ALL: comparison with standard morphologic analysis and risk group classification.
    Scrideli CA, Queiroz RG, Bernardes JE, Valera ET, Tone LG.
    Med Pediatr Oncol; 2003 Jul 01; 41(1):10-6. PubMed ID: 12764736
    [Abstract] [Full Text] [Related]

  • 13. [Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow].
    Schrappe M, Reiter A, Sauter S, Ludwig WD, Wörmann B, Harbott J, Bender-Götze C, Dörffel W, Dopfer R, Frey E.
    Klin Padiatr; 1994 Jul 01; 206(4):208-21. PubMed ID: 7526027
    [Abstract] [Full Text] [Related]

  • 14. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG).
    van der Does-van den Berg A, van Wering ER, Suciu S, Solbu G, van 't Veer MB, Rammeloo JA, de Koning J, van Zanen GE.
    Am J Pediatr Hematol Oncol; 1989 Jul 01; 11(2):125-33. PubMed ID: 2665546
    [Abstract] [Full Text] [Related]

  • 15. Early responses to chemotherapy of normal and malignant hematologic cells are prognostic in children with acute lymphoblastic leukemia.
    Laughton SJ, Ashton LJ, Kwan E, Norris MD, Haber M, Marshall GM.
    J Clin Oncol; 2005 Apr 01; 23(10):2264-71. PubMed ID: 15800317
    [Abstract] [Full Text] [Related]

  • 16. Treatment of high-risk acute lymphoblastic leukemia in children using the AL851 and ALHR88 protocols: a report from the Kyushu-Yamaguchi Children's Cancer Study Group in Japan.
    Matsuzaki A, Ishii E, Okamura J, Eguchi H, Yoshida N, Yanai F, Inoue T, Miyake K, Ishihara T, Tsuboi C.
    Med Pediatr Oncol; 1996 Jan 01; 26(1):10-9. PubMed ID: 7494507
    [Abstract] [Full Text] [Related]

  • 17. [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia].
    Ye QD, Gu LJ, Tang JY, Xue HL, Chen J, Pan C, Chen J, Dong L, Zhou M, Jiang LM.
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun 01; 10(3):333-6. PubMed ID: 18554462
    [Abstract] [Full Text] [Related]

  • 18. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
    Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A, Barth A, Borkhardt A, Peters C, Handgretinger R, Sykora KW, Holter W, Kabisch H, Klingebiel T, von Stackelberg A, ALL-REZ BFM Study Group.
    J Clin Oncol; 2009 Jan 20; 27(3):377-84. PubMed ID: 19064980
    [Abstract] [Full Text] [Related]

  • 19. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.
    Eckert C, von Stackelberg A, Seeger K, Groeneveld TW, Peters C, Klingebiel T, Borkhardt A, Schrappe M, Escherich G, Henze G.
    Eur J Cancer; 2013 Apr 20; 49(6):1346-55. PubMed ID: 23265714
    [Abstract] [Full Text] [Related]

  • 20. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.
    van Dongen JJ, Seriu T, Panzer-Grümayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, van Wering ER, Ludwig WD, Basso G, de Bruijn MA, Cazzaniga G, Hettinger K, van der Does-van den Berg A, Hop WC, Riehm H, Bartram CR.
    Lancet; 1998 Nov 28; 352(9142):1731-8. PubMed ID: 9848348
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.